377 related articles for article (PubMed ID: 12748830)
1. Impact of technology on the utilisation of positron emission tomography in lymphoma: current and future perspectives.
Visvikis D; Ell PJ
Eur J Nucl Med Mol Imaging; 2003 Jun; 30 Suppl 1():S106-16. PubMed ID: 12748830
[TBL] [Abstract][Full Text] [Related]
2. Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers.
Facey K; Bradbury I; Laking G; Payne E
Health Technol Assess; 2007 Oct; 11(44):iii-iv, xi-267. PubMed ID: 17999839
[TBL] [Abstract][Full Text] [Related]
3. CT-based attenuation correction in the calculation of semi-quantitative indices of [18F]FDG uptake in PET.
Visvikis D; Costa DC; Croasdale I; Lonn AH; Bomanji J; Gacinovic S; Ell PJ
Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):344-53. PubMed ID: 12634961
[TBL] [Abstract][Full Text] [Related]
4. PET imaging in pediatric Hodgkin's lymphoma.
Hudson MM; Krasin MJ; Kaste SC
Pediatr Radiol; 2004 Mar; 34(3):190-8. PubMed ID: 14745528
[TBL] [Abstract][Full Text] [Related]
5. [(18)F]FDG in childhood lymphoma: clinical utility and impact on management.
Montravers F; McNamara D; Landman-Parker J; Grahek D; Kerrou K; Younsi N; Wioland M; Leverger G; Talbot JN
Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1155-65. PubMed ID: 12192560
[TBL] [Abstract][Full Text] [Related]
6. Discrepancies and priorities in staging and restaging malignant lymphoma by SPET, SPET/CT, PET/CT and PET/MRI.
Chavdarova LI; Tzonevska AD; Piperkova EN
Hell J Nucl Med; 2013; 16(3):223-9. PubMed ID: 24137584
[TBL] [Abstract][Full Text] [Related]
7. Integrated whole-body PET/MR hybrid imaging: clinical experience.
Quick HH; von Gall C; Zeilinger M; Wiesmüller M; Braun H; Ziegler S; Kuwert T; Uder M; Dörfler A; Kalender WA; Lell M
Invest Radiol; 2013 May; 48(5):280-9. PubMed ID: 23442775
[TBL] [Abstract][Full Text] [Related]
8. The role of hybrid cameras in oncology.
Delbeke D; Sandler MP
Semin Nucl Med; 2000 Oct; 30(4):268-80. PubMed ID: 11105928
[TBL] [Abstract][Full Text] [Related]
9. Utility of fluorodeoxyglucose-PET imaging in the management of patients with Hodgkin's and non-Hodgkin's lymphomas.
Kumar R; Maillard I; Schuster SJ; Alavi A
Radiol Clin North Am; 2004 Nov; 42(6):1083-100. PubMed ID: 15488559
[TBL] [Abstract][Full Text] [Related]
10. The use of positron emission tomography with [18F] 2-fluoro-D-2-deoxyglucose (FDG-PET) in Hodgkin and non-Hodgkin's lymphoma.
Chiusolo P; Sica S; Leone G
Hematology; 2003 Dec; 8(6):403-8. PubMed ID: 14668036
[TBL] [Abstract][Full Text] [Related]
11. FDG-PET/CT in lymphoma.
Juweid ME
Methods Mol Biol; 2011; 727():1-19. PubMed ID: 21331925
[TBL] [Abstract][Full Text] [Related]
12. PET/CT: appropriate application in lymphoma.
Wang X
Chin Clin Oncol; 2015 Mar; 4(1):4. PubMed ID: 25841711
[TBL] [Abstract][Full Text] [Related]
13. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF
Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
[TBL] [Abstract][Full Text] [Related]
14. Fluorodeoxyglucose positron emission tomography (FDG-PET) and PET/computed tomography imaging characteristics of thyroid lymphoma and their potential clinical utility.
Basu S; Li G; Bural G; Alavi A
Acta Radiol; 2009 Mar; 50(2):201-4. PubMed ID: 19089692
[TBL] [Abstract][Full Text] [Related]
15. Impact of computed tomography and 18F-deoxyglucose coincidence detection emission tomography image fusion for optimization of conformal radiotherapy in non-small-cell lung cancer.
Deniaud-Alexandre E; Touboul E; Lerouge D; Grahek D; Foulquier JN; Petegnief Y; Grès B; El Balaa H; Keraudy K; Kerrou K; Montravers F; Milleron B; Lebeau B; Talbot JN
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1432-41. PubMed ID: 16125870
[TBL] [Abstract][Full Text] [Related]
16. FDG PET/CT imaging as a biomarker in lymphoma.
Meignan M; Itti E; Gallamini A; Younes A
Eur J Nucl Med Mol Imaging; 2015 Apr; 42(4):623-33. PubMed ID: 25573631
[TBL] [Abstract][Full Text] [Related]
17. Instrumentation for coincidence imaging with multihead scintillation cameras.
Patton JA
Semin Nucl Med; 2000 Oct; 30(4):239-54. PubMed ID: 11105926
[TBL] [Abstract][Full Text] [Related]
18. PET/CT in oncology: integration into clinical management of lymphoma, melanoma, and gastrointestinal malignancies.
Schöder H; Larson SM; Yeung HW
J Nucl Med; 2004 Jan; 45 Suppl 1():72S-81S. PubMed ID: 14736838
[TBL] [Abstract][Full Text] [Related]
19. Value of iterative reconstruction, attenuation correction, and image fusion in the interpretation of FDG PET images with an integrated dual-head coincidence camera and X-ray-based attenuation maps.
Delbeke D; Martin WH; Patton JA; Sandler MP
Radiology; 2001 Jan; 218(1):163-71. PubMed ID: 11152796
[TBL] [Abstract][Full Text] [Related]
20. [Clinical value of FDG PET using coincident gamma cameras in staging and restaging of malignant lymphoma--compared with convenitonal diagnostic methods].
Pichler R; Maschek W; Hatzl-Griesenhofer M; Huber H; Wimmer G; Wahl G; Fridrik M
Nuklearmedizin; 2000 Sep; 39(6):166-73. PubMed ID: 11057408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]